Pfizer's Direct-To-Consumer Digital Platform Not Limited To Its Own Treatment Options

 
• By Jessica Merrill and Cathy Kelly

The launch of Pfizer's new direct-to-consumer program for vaccines and migraine drugs follows the introduction of Eli Lilly's LillyDirect in January. Company-branded initiatives are careful to partner with third-party vendors and allow the use of treatments marketed by other companies to avoid compliance pitfalls. 

Pfizer is launching an end-to-end digital platform for some of its medicines and vaccines. • Source: Shutterstock

Pfizer Inc.’s new digital treatment platform was unveiled to make some of its vaccines and medicines available to patients faster and more conveniently. But the program will not limit the treatment options available through the program to Pfizer products or constrain the options recommended by participating clinicians to help ensure compliance with US Food and Drug Administration regulations on promotion.

Announced 27 August, the PfizerForAll system can connect patients to health care providers for same-day appointments and deliver vaccines, medicines and

More from Marketing & Advertising

More from Compliance